Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

In ASCOT study, lipid lowering with a statin provided additional beneficial effects in hypertensive patients with average levels of serum total cholesterol. However, the underlying mechanism of statins to improve clinical outcomes in hypertension is unclear and the effect of statins on coronary flow reserve (CFR) has not been examined in hypertensive patients. Therefore, it is clinically important and timely project to measure CFR non-invasively using echocardiography and to elucidate the mechanism of clinical benefits of statins in hypertensive patients with cardiovascular risk. The investigators try to evaluate the effect of rosuvastatin on CFR by measuring the change of CFR after 1 year treatment of rosuvastatin, and to correlate CFR with LDL-cholesterol and CRP.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asan Medical Center
• Collaborator: AstraZeneca
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Controlled Hypertension: treated SBP < 140 mmHg and DBP < 90 mmHg

• LDL cholesterol > 130 mg/dL

• Patients with statin-naive state, defined as receiving no statin therapy for more than 3 months during the previous 12 months

• Any 1 of these cardiovascular risk factors required: smoking, Type 2 DM, age over 55 (men) or 65 (women), peripheral vascular disease, history of cerebrovascular event, family history of early CHD before age 55, HDL cholesterol < 40 mg/dL

Exclusion Criteria:

• A previous history of intolerance or hypersensitivity to statins

• Uncontrolled hypertension; SBP ≥ 140 mmHg or DBP ≥ 90 mmHg

• Previous MI or currently treated angina pectoris

• Stroke, Transient ischemic attack < 3 months

• Secondary hypertension

• Fasting serum triglyceride > 500 mg/dL

• Clinical congestive heart failure

• Uncontrolled arrhythmia

• Left ventricular hypertrophy: LV mass index > 134g/m2 (male) or >110g/m2 (female)

• Concomitant clinically important respiratory, hematological, gastrointestinal, hepatic, renal or other disease

• Pregnant or lactating women and those of child-bearing potential